Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation

被引:62
作者
Mahle, WT
Vincent, RN
Berg, AM
Kanter, KR
机构
[1] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Pediat, Div Cardiol, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Dept Surg, Div Cardiothorac Surg, Atlanta, GA 30322 USA
关键词
D O I
10.1016/j.healun.2003.10.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hydroxymethylglutaryl CoA reductase inhibitors (statins) have been demonstrated to reduce the risk of developing coronary allograft vasculopathy (CAV) following heart transplantation in adults and are used routinely in many centers. CAV and lipid abnormalities have been reported to be less prevalent in pediatric heart transplant recipients. It is not known whether statins reduce the risk of CAV in this population Methods: A retrospective review was performed to analyze the risk factors for developing CAV following pediatric heart transplantation with particular attention to the impact of pravastatin therapy. The study population was comprised of 129 pediatric patients who underwent 142 heart transplants at our institution from 1988 to 2003. The outcome variable was freedom from CAV, CAV being determined by coronary angiography or autopsy. Results: CAV was identified in 25 recipients at a median of 3.7 years after transplantation. There were 331 patient-years of pravastatin therapy. Pravastatin therapy resulted in a reduction in total cholesterol levels, 162 +/- 29 to 137 +/- 20 mg/dl, p = 0.01. In multivariate analysis the use of pravastatin was associated with a lower incidence of CAV (p = 0.03). whereas an increased frequency of late rejection (p = 0.003) and earlier year of transplantation (p = 0.04) were associated with increased risk of CAV. Conclusions: The routine use of pravastatin was associated with a lower risk following pediatric heart transplantation. Further studies into the relationship between lipid abnormalities. inflammation and rejection, and the development of CAV in children are warranted. Copyright (C) 2005 by the International Society for Heart and Lung Transplantation.
引用
收藏
页码:63 / 66
页数:4
相关论文
共 15 条
[1]  
ADDONIZIO LJ, 1993, CIRCULATION, V88, P224
[2]   Efficacy and safety of atorvastatin after pediatric heart transplantation [J].
Chin, C ;
Gamberg, P ;
Miller, J ;
Luikart, H ;
Bernstein, D .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (11) :1213-1217
[3]   COVARIANCE ANALYSIS OF HEART-TRANSPLANT SURVIVAL DATA [J].
CROWLEY, J ;
HU, M .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1977, 72 (357) :27-36
[4]   Ten year survival after heart transplantation: palliative procedure or successful long term treatment? [J].
Fraund, S ;
Pethig, K ;
Franke, U ;
Wahlers, T ;
Harringer, W ;
Cremer, J ;
Fieguth, HG ;
Oppelt, P ;
Haverich, A .
HEART, 1999, 82 (01) :47-51
[5]  
Hirsch R., 2001, Journal of Heart and Lung Transplantation, V20, P261, DOI 10.1016/S1053-2498(00)00603-3
[6]  
KATZNELSON S, 1991, TRANSPL P S, V31, pS22
[7]   EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION [J].
KOBASHIGAWA, JA ;
KATZNELSON, S ;
LAKS, H ;
JOHNSON, JA ;
YEATMAN, L ;
WANG, XM ;
CHIA, D ;
TERASAKI, PI ;
SABAD, A ;
COGERT, GA ;
TROSIAN, K ;
HAMILTON, MA ;
MORIGUCHI, JD ;
KAWATA, N ;
HAGE, A ;
DRINKWATER, DC ;
STEVENSON, LW .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) :621-627
[8]   Role of statins in the management of dyslipidemia after cardiac transplant: Randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin [J].
Magnani, G ;
Carinci, V ;
Magelli, C ;
Potena, L ;
Reggiani, LB ;
Branzi, A .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (07) :710-715
[9]   Late rejection is a predictor of transplant coronary artery disease in children [J].
Mulla, NF ;
Johnston, JK ;
Vander Dussen, L ;
Beeson, WL ;
Chinnock, RE ;
Bailey, LL ;
Larsen, RL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (01) :243-250
[10]  
Pahl E, 2002, CIRCULATION, V106, P396